

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |  |  |
|--|--|--|
| 1. Name and Address of Reporting Person*<br><u>ALTSHULER DAVID</u><br><br>(Last) (First) (Middle)<br><u>C/O VERTEX PHARMACEUTICALS INCORPORATED</u><br><u>50 NORTHERN AVENUE</u><br><br>(Street)<br><u>BOSTON MA 02210</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>VERTEX PHARMACEUTICALS INC / MA [ VRTX ]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><br>Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><u>EVP, Global Research and CSO</u> |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>02/17/2020</u>                          |  |
|  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                       |  |
| 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br>Form filed by More than One Reporting Person  |  |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                            | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|----------------------------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                      |   |  |   |
| Common Stock                    | 02/17/2020                           |  | F                              |   | 2,496   | D          | \$241.5                    | 37,474  | D  |   |
| Common Stock                    | 02/18/2020                           |  | S <sup>(1)</sup>               |   | 400   | D          | \$241.8 <sup>(2)(3)</sup>  | 37,074  | D  |   |
| Common Stock                    | 02/18/2020                           |  | S <sup>(1)</sup>               |   | 1,010   | D          | \$242.62 <sup>(3)(4)</sup> | 36,064  | D  |   |
| Common Stock                    | 02/18/2020                           |  | S <sup>(1)</sup>               |   | 530   | D          | \$243.66 <sup>(3)(5)</sup> | 35,534  | D  |   |
| Common Stock                    | 02/18/2020                           |  | S <sup>(1)</sup>               |   | 632   | D          | \$244.87 <sup>(3)(6)</sup> | 34,902  | D  |   |
| Common Stock                    | 02/18/2020                           |  | S <sup>(1)</sup>               |   | 556   | D          | \$245.57 <sup>(3)(7)</sup> | 34,346  | D  |   |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date |   |  |  |   |  |

**Explanation of Responses:**

- Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of \$241.80 (range \$241.24 to \$242.23).
- Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$242.62 (range \$242.24 to \$243.21).
- Open market sales reported on this line occurred at a weighted average price of \$243.66 (range \$243.24 to \$244.15).
- Open market sales reported on this line occurred at a weighted average price of \$244.87 (range \$244.28 to \$245.26).
- Open market sales reported on this line occurred at a weighted average price of \$245.57 (range \$245.28 to \$245.86).

**Remarks:**

/s/ Omar White, Attorney-in-Fact 02/19/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.